Growth Metrics

Halozyme Therapeutics (HALO) Gains from Investment Securities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Gains from Investment Securities for 15 consecutive years, with -$15000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 100.02% to -$15000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $410000.0 through Dec 2025, down 99.49% year-over-year, with the annual reading at $410000.0 for FY2025, 99.49% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$15000.0 at Halozyme Therapeutics, down from $425000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $78.0 million in Q4 2024, with the low at -$3.3 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is $5.6 million, with a median of $500000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 2424.96% in 2024, then crashed 439.92% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $500000.0 in 2021, then surged by 2950.8% to $15.3 million in 2022, then crashed by 79.75% to $3.1 million in 2023, then skyrocketed by 2424.96% to $78.0 million in 2024, then tumbled by 100.02% to -$15000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$15000.0, $425000.0, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.